

Special thanks to Dr. Melisi and the team from Centro Ricerche Cliniche di Verona for recruiting most patients in the trial so far.

Verona, Italy – June 10th 2020

“We are very proud to be part of the FIGHT-302 team” said Professor Davide Melisi, medical oncologist and principal investigator of the trial carried out at the University of Verona, Italy, “and thrilled by the activity showed by pemigatinib in patients with FGFR2 mutated cholangiocarcinoma.”

The hepatobiliary cancer multidisciplinary team in Verona includes medical oncologists and surgeons with worldwide recognized experience in biliary tract tumors such as Professor Alfredo Guglielmi and Professor Andrea Ruzzenente. “Our group is a reference point for the treatment of liver cancers in Italy and we believe that genomic profiling can make the difference in the clinical management of patients affected by cholangiocarcinoma” said Professor Guglielmi.

At the University Hospital of Verona, the FIGHT-302 trial is conducted at “Centro Ricerche Cliniche - CRC”, a unit fully dedicated to clinical trials with data managers, nurses and medical oncologists such as Dr. Camilla Zecchetto. “In our daily practice all cases with cholangiocarcinoma are discussed within our multidisciplinary team, which includes surgeons, oncologists, pathologists, radiologists and radiotherapists” said Dr. Zecchetto. “We usually select for pre-screening through NGS patients with metastatic disease at first diagnosis, as well as those undergoing surgery but presenting a high risk of recurrence, in particular with clinical characteristics such as younger age and female gender, which are associated with a higher chance of FGFR rearrangements. Pre-screening such patients allows prompt enrollment in case of tumor recurrence”.

“No secrets for the good enrollment rate at our center, it’s all about being team players” said Professor Melisi. “The close collaboration within our multidisciplinary team is one of our main strengths, enabling us to provide patients with the best research-driven care available. FIGHT-302 trial has the potential to be a practice-changing study in cholangiocarcinoma and we will keep offering the enrollment to all our new patients”.



(pictured left to the right are: Prof. Davide Melisi - Medical Oncology; Cristiana Piazzola, CRC; Dr. Camilla Zecchetto, Medical Oncology; Dr. Stefano Milleri, CRC; Martina Pasquato, CRC; Morena Gianfortone, CRC; Prof. Guglielmi and Prof. Andrea Ruzzenente - General and Epatobilliary Surgery).

*Kind Regards,
The Incyte and IQVIA Teams*